Wanted: Orphan Drugs, Antivirals Dominate China's Latest Fast Track List
Half of the newly selected imported drugs slated for fast track review in China are rare disease treatments, followed by antiviral drugs for influenza and HIV, reflecting key medical needs in the country.
You may also be interested in...
Evolving regulations and emerging opportunities appear to have put China firmly on the radar of several frontline Indian firms. Sun Pharma is the latest to join those seeking a larger play in the Asian market.
As China is poised to supply globally medical products to fight coronavirus, a battle to banish its image of poor product quality is on.
China insurance giant snatches up stakes in Japanese pharma and a traditional Chinese medicines maker with a $465m spending spree.